Covid-19 roundup: Roche's Actemra marred by negative results; Here comes another single-armed remdesivir trial
Despite initial promising signs, Roche’s Actemra appears unable to escape the fate of Sanofi and Regeneron’s IL-6 Kevzara, as it failed to reduce severe respiratory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
